Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study investigating efficacy and safety of Cytotect FH, nanometer filtered (BT094)

    Summary
    EudraCT number
    2007-004692-19
    Trial protocol
    DE   BE   HU   AT   IT  
    Global end of trial date
    22 Dec 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    13 Dec 2021
    First version publication date
    13 Dec 2021
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    963
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Biotest AG
    Sponsor organisation address
    Landsteinerstr. 5, Dreieich, Germany, 63303
    Public contact
    Andrea Wartenberg-Demand, MD, PhD VP CCR&D Landsteinerstr. 5 63303 Dreieich, Biotest AG, 49 06103801497, andrea.wartenberg-demand@biotest.com
    Scientific contact
    Andrea Wartenberg-Demand, MD, PhD VP CCR&D Landsteinerstr. 5 63303 Dreieich, Biotest AG, 49 06103801497, andrea.wartenberg-demand@biotest.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    16 Mar 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    22 Dec 2016
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Dec 2016
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    Prevention of congenital CMV infection in infants of mothers with primary CMV infection during pregnancy. The number (percentage) of newborns/foetuses with congenital CMV infection is defined as the primary efficacy paramter.
    Protection of trial subjects
    none
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Mar 2008
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 2375
    Country: Number of subjects enrolled
    Belgium: 3600
    Country: Number of subjects enrolled
    Germany: 8318
    Country: Number of subjects enrolled
    Hungary: 1024
    Country: Number of subjects enrolled
    Italy: 157
    Worldwide total number of subjects
    15474
    EEA total number of subjects
    15474
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    15474
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Date of first enrolment: 08-OCT-2008; date of last completed: 22-DEC-2016

    Pre-assignment
    Screening details
    Pregnant women, CMV-specific IgG seronegative pregnant women at Screening, Gestational age ≤ 13 w+6 d, 18 to 45 years of Age, written informed consent. In total, 15,474 pregnant women were screened. Out of these, 9,535 pregnant women were randomized, to either Group A (BT094 treatment group) or Group B (“standard of care”), in a 1:1 ratio

    Period 1
    Period 1 title
    Screening
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Group A (BT094)
    Arm description
    Regular CMV-Screening after randomization (only CMV-negative women)
    Arm type
    Experimental

    Investigational medicinal product name
    BT094
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Two doses of BT094 of 2 x 200 U/kg body weight (BW) intravenously at an interval of 14 days. The first dose had to be administered within 7 days after confirmed CMV seroconversion. A third administration 28 days after second administration was optional.

    Arm title
    Group B (standard of care)
    Arm description
    No regular CMV-Screening after randomization (only CMV-negative subjects)
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 1 [1]
    Group A (BT094) Group B (standard of care)
    Started
    4800
    4735
    Completed
    4800
    4735
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Only subjects that had been test seronegative for CMV entered screening phase
    Period 2
    Period 2 title
    Treatment period
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Group A (BT094)
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    BT094
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Two doses of BT094 of 2 x 200 U/kg body weight (BW) intravenously at an interval of 14 days. The first dose had to be administered within 7 days after confirmed CMV seroconversion. A third administration 28 days after second administration was optional.

    Arm title
    Group B (standard of care)
    Arm description
    -
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 2 [2]
    Group A (BT094) Group B (standard of care)
    Started
    45
    35
    Completed
    45
    35
    Notes
    [2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: Only subjects with seroconversion during the study entered treatment period
    Period 3
    Period 3 title
    Follow-up (newborns)
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Group A (BT094)
    Arm description
    -
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Group B (standard of care)
    Arm description
    -
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 3
    Group A (BT094) Group B (standard of care)
    Started
    45
    35
    Completed
    45
    35

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Group A (BT094)
    Reporting group description
    Regular CMV-Screening after randomization (only CMV-negative women)

    Reporting group title
    Group B (standard of care)
    Reporting group description
    No regular CMV-Screening after randomization (only CMV-negative subjects)

    Reporting group values
    Group A (BT094) Group B (standard of care) Total
    Number of subjects
    4800 4735 9535
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    4800 4735 9535
        From 65-84 years
    0 0 0
        85 years and over
    0 0 0
    Gender categorical
    Units: Subjects
        Female
    4800 4735 9535
        Male
    0 0 0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Group A (BT094)
    Reporting group description
    Regular CMV-Screening after randomization (only CMV-negative women)

    Reporting group title
    Group B (standard of care)
    Reporting group description
    No regular CMV-Screening after randomization (only CMV-negative subjects)
    Reporting group title
    Group A (BT094)
    Reporting group description
    -

    Reporting group title
    Group B (standard of care)
    Reporting group description
    -
    Reporting group title
    Group A (BT094)
    Reporting group description
    -

    Reporting group title
    Group B (standard of care)
    Reporting group description
    -

    Primary: Number of CMV-infected foetuses and newborns

    Close Top of page
    End point title
    Number of CMV-infected foetuses and newborns
    End point description
    End point type
    Primary
    End point timeframe
    Number of CMV-infected foetuses and newborns from seroconverted mothers. Confirmation of presence or absence of CMV infection was assessed by using PCR in urinalysis of the newborn, or by using PCR in the amniotic fluid.
    End point values
    Group A (BT094) Group B (standard of care)
    Number of subjects analysed
    45
    28
    Units: Number of CMV-infected foetuses and newb
    16
    13
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Group A (BT094) v Group B (standard of care)
    Number of subjects included in analysis
    73
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    > 0.05
    Method
    Fisher exact
    Confidence interval

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Treatment-emergent AEs were to be recorded from the start of treatment in group A and from the time of detected seroconversion of the mother in group B until last follow-up visit of the newborn in both groups.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.1
    Reporting groups
    Reporting group title
    Group A (BT094) mothers
    Reporting group description
    -

    Reporting group title
    Group B (standard of care) mothers
    Reporting group description
    -

    Reporting group title
    Group A (BT094) foetuses
    Reporting group description
    -

    Reporting group title
    Group B (stardard of care) foetuses
    Reporting group description
    -

    Reporting group title
    Group A (BT094) newborn
    Reporting group description
    -

    Reporting group title
    Group B (standard of care) newborn
    Reporting group description
    -

    Serious adverse events
    Group A (BT094) mothers Group B (standard of care) mothers Group A (BT094) foetuses Group B (stardard of care) foetuses Group A (BT094) newborn Group B (standard of care) newborn
    Total subjects affected by serious adverse events
         subjects affected / exposed
    15 / 45 (33.33%)
    7 / 34 (20.59%)
    6 / 45 (13.33%)
    2 / 34 (5.88%)
    10 / 45 (22.22%)
    5 / 34 (14.71%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Breast cancer
         subjects affected / exposed
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ovarian adenoma
         subjects affected / exposed
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Caesarean section
         subjects affected / exposed
    9 / 45 (20.00%)
    4 / 34 (11.76%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 9
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Failed trial of labour
         subjects affected / exposed
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Postpartum haemorrhage
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Breech presentation
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Complication of delivery
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foetal distress syndrome
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Premature labour
         subjects affected / exposed
    4 / 45 (8.89%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foetal acidosis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Neonatal respiratory failure
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Nuclear magnetic resonance imaging brain abnormal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otoacoustic emissions test abnormal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Perineal injury
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skull fracture
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subarachnoid haemorrhage
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Congenital, familial and genetic disorders
    Foetal cystic hygroma
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypersplenism congenital
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Congenital central nervous system anomaly
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Congenital cytomegalovirus infection
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    2 / 34 (5.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Kidney duplex
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subependymal nodular heterotopia
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Bradycardia foetal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nonreassuring foetal heart rate pattern
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebral ventricle dilatation
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Splenomegaly
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Haemorrhoids
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatomegaly
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Proteinuria
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelocaliectasis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Hypotonia neonatal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Cytomegalovirus infection
         subjects affected / exposed
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 45 (2.22%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adenovirus infection
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchiolitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cytomegalovirus hepatitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterovirus infection
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteomyelitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory syncytial virus bronchiolitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    Group A (BT094) mothers Group B (standard of care) mothers Group A (BT094) foetuses Group B (stardard of care) foetuses Group A (BT094) newborn Group B (standard of care) newborn
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    30 / 45 (66.67%)
    9 / 34 (26.47%)
    7 / 45 (15.56%)
    4 / 34 (11.76%)
    36 / 45 (80.00%)
    19 / 34 (55.88%)
    Surgical and medical procedures
    Caesarean section
         subjects affected / exposed
    9 / 45 (20.00%)
    4 / 34 (11.76%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    9
    4
    0
    0
    0
    0
    Pregnancy, puerperium and perinatal conditions
    Premature labour
         subjects affected / exposed
    5 / 45 (11.11%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    5
    0
    0
    0
    0
    0
    Uterine contractions during pregnancy
         subjects affected / exposed
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    Jaundice neonatal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    Breech presentation
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Foetal distress syndrome
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    5 / 45 (11.11%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    5
    0
    0
    0
    0
    0
    Pyrexia
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    3 / 45 (6.67%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    3
    0
    Psychiatric disorders
    Sleep disorder
         subjects affected / exposed
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    Investigations
    Nuclear magnetic resonance imaging brain abnormal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    Foetal heart rate abnormal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Injury, poisoning and procedural complications
    Perineal injury
         subjects affected / exposed
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    Vulval laceration
         subjects affected / exposed
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Congenital, familial and genetic disorders
    Foetal cystic hygroma
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    Congenital central nervous system anomaly
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    2
    1
    Congenital cytomegalovirus infection
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    1
    2
    Cardiac disorders
    Bradycardia foetal
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    Nervous system disorders
    headache
         subjects affected / exposed
    3 / 45 (6.67%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    Cerebral ventricle dilatation
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    3
    0
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    2 / 45 (4.44%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    3
    1
    0
    0
    0
    0
    Anaemia of pregnancy
         subjects affected / exposed
    1 / 45 (2.22%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    Splenomegaly
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    2
    0
    1
    1
    Ear and labyrinth disorders
    Middle ear effusion
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    7 / 45 (15.56%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    7
    1
    Eye disorders
    Astigmatism
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    2
    1
    Retinal haemorrhage
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Gastrointestinal disorders
    Dyspepsia
         subjects affected / exposed
    3 / 45 (6.67%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    Haemorrhoids
         subjects affected / exposed
    2 / 45 (4.44%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    Nausea
         subjects affected / exposed
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    Constipation
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    1
    2
    Diarrhoea
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Hepatobiliary disorders
    Hepatomegaly
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Eczema
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    3 / 45 (6.67%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    3
    0
    Rash
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 45 (2.22%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    2 / 45 (4.44%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    5 / 45 (11.11%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    5 / 45 (11.11%)
    2 / 34 (5.88%)
         occurrences all number
    5
    0
    0
    0
    5
    2
    Bronchiolitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    3
    0
    Conjunctivitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    3
    0
    Ear infection
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    6 / 45 (13.33%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    7
    3
    Gastroenteritis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Otitis media
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    5 / 45 (11.11%)
    4 / 34 (11.76%)
         occurrences all number
    0
    0
    0
    0
    7
    5
    Rhinitis
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    2 / 45 (4.44%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    2
    1
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    4 / 45 (8.89%)
    4 / 34 (11.76%)
         occurrences all number
    0
    0
    0
    0
    4
    4
    Varicella
         subjects affected / exposed
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    1 / 45 (2.22%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Cytomegalovirus infection
         subjects affected / exposed
    0 / 45 (0.00%)
    1 / 34 (2.94%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
    0 / 45 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    07 Jan 2008
    Cytotect Biotest was introduced as optional off-Label Treatment in Group B for ethical reasons instead of the investigational product BT094 due to regulatory reasons.
    30 Jun 2014
    Introduction of planned recruitment stop after approval of amendment. Change in the recording of Adverse Events for Group B.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 12:58:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA